A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies

Junko Kizu, Yoshihiro Yamakawa, Kayoko Maezawa, Tomoko Terajima, Masaki Yoshida, Seiji Hori

Research output: Contribution to journalArticle

Abstract

In September 2004, when the precautions in the package inserts of injectable antibiotics were partially revised, the phrase "it is advisable to conduct an intracutaneous reaction test beforehand" or "conduct an intracutaneous reaction test beforehand" was deleted and replaced by precautions against allergic reactions and instructions to promptly deal with onsets of such reactions. However, intracutaneous reaction test solutions for injectable antibiotics are still manufactured and supplied to medical institutions. In this study, we conducted a questionnaire survey involving hospital pharmacies throughout Japan on their use of intracutaneous reaction tests and storage of intracutaneous reaction test solutions. In March 2010, we sent a written questionnaire by mail to 1,000 medical institutions with beds throughout Japan, which were extracted by region and the number of beds. We received answers from 448 institutions, comprised of 346 institutions which had stopped conducting intracutaneous reaction tests, 32 institutions which conducted tests in accordance with doctors' decisions and patients' history of allergy, and 25 institutions which basically conducted tests. The test implementation rate was higher at institutions with fewer beds and institutions without the ICT. A total of 158 institutions regularly stocked intracutaneous reaction test solutions. Among them, they stocked the solutions at an average of 12.6 items. Fifty-four institutions ordered the solutions as required. Thus, we observed that the majority of the hospital pharmacies used intracutaneous reaction test solutions and were faced with various associated problems. The Japanese Society of Chemotherapy also commented that "the use of intracutaneous reaction tests as a means to predict anaphylactic shock should be discontinued without delay". It is also necessary to appeal to the pharmaceutical industry to support the movement to stop using intracutaneous reaction test solutions.

Original languageEnglish
Pages (from-to)366-373
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume59
Issue number4
Publication statusPublished - 2011 Jul

Fingerprint

Pharmacies
Japan
Hypersensitivity
Product Labeling
Anti-Bacterial Agents
Injections
Drug Industry
Postal Service
Anaphylaxis
Surveys and Questionnaires
Drug Therapy

Keywords

  • Drug allergy
  • Intracutaneous reaction test
  • Questionnaire

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Kizu, J., Yamakawa, Y., Maezawa, K., Terajima, T., Yoshida, M., & Hori, S. (2011). A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies. Japanese Journal of Chemotherapy, 59(4), 366-373.

A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies. / Kizu, Junko; Yamakawa, Yoshihiro; Maezawa, Kayoko; Terajima, Tomoko; Yoshida, Masaki; Hori, Seiji.

In: Japanese Journal of Chemotherapy, Vol. 59, No. 4, 07.2011, p. 366-373.

Research output: Contribution to journalArticle

Kizu, J, Yamakawa, Y, Maezawa, K, Terajima, T, Yoshida, M & Hori, S 2011, 'A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies', Japanese Journal of Chemotherapy, vol. 59, no. 4, pp. 366-373.
Kizu J, Yamakawa Y, Maezawa K, Terajima T, Yoshida M, Hori S. A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies. Japanese Journal of Chemotherapy. 2011 Jul;59(4):366-373.
Kizu, Junko ; Yamakawa, Yoshihiro ; Maezawa, Kayoko ; Terajima, Tomoko ; Yoshida, Masaki ; Hori, Seiji. / A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies. In: Japanese Journal of Chemotherapy. 2011 ; Vol. 59, No. 4. pp. 366-373.
@article{ea520b48c097497ea305eb17cccdaa7c,
title = "A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies",
abstract = "In September 2004, when the precautions in the package inserts of injectable antibiotics were partially revised, the phrase {"}it is advisable to conduct an intracutaneous reaction test beforehand{"} or {"}conduct an intracutaneous reaction test beforehand{"} was deleted and replaced by precautions against allergic reactions and instructions to promptly deal with onsets of such reactions. However, intracutaneous reaction test solutions for injectable antibiotics are still manufactured and supplied to medical institutions. In this study, we conducted a questionnaire survey involving hospital pharmacies throughout Japan on their use of intracutaneous reaction tests and storage of intracutaneous reaction test solutions. In March 2010, we sent a written questionnaire by mail to 1,000 medical institutions with beds throughout Japan, which were extracted by region and the number of beds. We received answers from 448 institutions, comprised of 346 institutions which had stopped conducting intracutaneous reaction tests, 32 institutions which conducted tests in accordance with doctors' decisions and patients' history of allergy, and 25 institutions which basically conducted tests. The test implementation rate was higher at institutions with fewer beds and institutions without the ICT. A total of 158 institutions regularly stocked intracutaneous reaction test solutions. Among them, they stocked the solutions at an average of 12.6 items. Fifty-four institutions ordered the solutions as required. Thus, we observed that the majority of the hospital pharmacies used intracutaneous reaction test solutions and were faced with various associated problems. The Japanese Society of Chemotherapy also commented that {"}the use of intracutaneous reaction tests as a means to predict anaphylactic shock should be discontinued without delay{"}. It is also necessary to appeal to the pharmaceutical industry to support the movement to stop using intracutaneous reaction test solutions.",
keywords = "Drug allergy, Intracutaneous reaction test, Questionnaire",
author = "Junko Kizu and Yoshihiro Yamakawa and Kayoko Maezawa and Tomoko Terajima and Masaki Yoshida and Seiji Hori",
year = "2011",
month = "7",
language = "English",
volume = "59",
pages = "366--373",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "4",

}

TY - JOUR

T1 - A questionnaire survey on the use of intracutaneous reaction tests at hospital pharmacies

AU - Kizu, Junko

AU - Yamakawa, Yoshihiro

AU - Maezawa, Kayoko

AU - Terajima, Tomoko

AU - Yoshida, Masaki

AU - Hori, Seiji

PY - 2011/7

Y1 - 2011/7

N2 - In September 2004, when the precautions in the package inserts of injectable antibiotics were partially revised, the phrase "it is advisable to conduct an intracutaneous reaction test beforehand" or "conduct an intracutaneous reaction test beforehand" was deleted and replaced by precautions against allergic reactions and instructions to promptly deal with onsets of such reactions. However, intracutaneous reaction test solutions for injectable antibiotics are still manufactured and supplied to medical institutions. In this study, we conducted a questionnaire survey involving hospital pharmacies throughout Japan on their use of intracutaneous reaction tests and storage of intracutaneous reaction test solutions. In March 2010, we sent a written questionnaire by mail to 1,000 medical institutions with beds throughout Japan, which were extracted by region and the number of beds. We received answers from 448 institutions, comprised of 346 institutions which had stopped conducting intracutaneous reaction tests, 32 institutions which conducted tests in accordance with doctors' decisions and patients' history of allergy, and 25 institutions which basically conducted tests. The test implementation rate was higher at institutions with fewer beds and institutions without the ICT. A total of 158 institutions regularly stocked intracutaneous reaction test solutions. Among them, they stocked the solutions at an average of 12.6 items. Fifty-four institutions ordered the solutions as required. Thus, we observed that the majority of the hospital pharmacies used intracutaneous reaction test solutions and were faced with various associated problems. The Japanese Society of Chemotherapy also commented that "the use of intracutaneous reaction tests as a means to predict anaphylactic shock should be discontinued without delay". It is also necessary to appeal to the pharmaceutical industry to support the movement to stop using intracutaneous reaction test solutions.

AB - In September 2004, when the precautions in the package inserts of injectable antibiotics were partially revised, the phrase "it is advisable to conduct an intracutaneous reaction test beforehand" or "conduct an intracutaneous reaction test beforehand" was deleted and replaced by precautions against allergic reactions and instructions to promptly deal with onsets of such reactions. However, intracutaneous reaction test solutions for injectable antibiotics are still manufactured and supplied to medical institutions. In this study, we conducted a questionnaire survey involving hospital pharmacies throughout Japan on their use of intracutaneous reaction tests and storage of intracutaneous reaction test solutions. In March 2010, we sent a written questionnaire by mail to 1,000 medical institutions with beds throughout Japan, which were extracted by region and the number of beds. We received answers from 448 institutions, comprised of 346 institutions which had stopped conducting intracutaneous reaction tests, 32 institutions which conducted tests in accordance with doctors' decisions and patients' history of allergy, and 25 institutions which basically conducted tests. The test implementation rate was higher at institutions with fewer beds and institutions without the ICT. A total of 158 institutions regularly stocked intracutaneous reaction test solutions. Among them, they stocked the solutions at an average of 12.6 items. Fifty-four institutions ordered the solutions as required. Thus, we observed that the majority of the hospital pharmacies used intracutaneous reaction test solutions and were faced with various associated problems. The Japanese Society of Chemotherapy also commented that "the use of intracutaneous reaction tests as a means to predict anaphylactic shock should be discontinued without delay". It is also necessary to appeal to the pharmaceutical industry to support the movement to stop using intracutaneous reaction test solutions.

KW - Drug allergy

KW - Intracutaneous reaction test

KW - Questionnaire

UR - http://www.scopus.com/inward/record.url?scp=80051539000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051539000&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:80051539000

VL - 59

SP - 366

EP - 373

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 4

ER -